Literature DB >> 16625649

Nicobrevin for smoking cessation.

L F Stead1, T Lancaster.   

Abstract

BACKGROUND: Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
OBJECTIVES: The objective of this review was to assess the effects of Nicobrevin on long term smoking cessation SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register. SELECTION CRITERIA: Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up. DATA COLLECTION AND ANALYSIS: Data were sought on the outcome, method of randomization, and completeness of follow up. MAIN
RESULTS: We identified no trials meeting the full inclusion criteria including long-term follow up. AUTHORS'
CONCLUSIONS: There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625649      PMCID: PMC6486288          DOI: 10.1002/14651858.CD005990

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  3 in total

1.  Outcome criteria in smoking cessation trials: proposal for a common standard.

Authors:  Robert West; Peter Hajek; Lindsay Stead; John Stapleton
Journal:  Addiction       Date:  2005-03       Impact factor: 6.526

2.  A double-blind, placebo-controlled study to determine the efficacy of Nicobrevin anti-smoking capsules.

Authors:  E Dankwa; L Perry; A Perkins
Journal:  Br J Clin Pract       Date:  1988-09

3.  [Medical support of nicotine withdrawal. Report on a double blind trail in over 5000 smokers (author's transl)].

Authors:  F Schmidt
Journal:  MMW Munch Med Wochenschr       Date:  1974-03-15
  3 in total
  6 in total

1.  [Guidelines for smoking cessation - update 2010].

Authors:  Alfred Lichtenschopf
Journal:  Wien Klin Wochenschr       Date:  2011-05-16       Impact factor: 1.704

Review 2.  Interventions for promoting smoking cessation during pregnancy.

Authors:  Judith Lumley; Catherine Chamberlain; Therese Dowswell; Sandy Oliver; Laura Oakley; Lyndsey Watson
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

3.  Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.

Authors:  Tatsuya Nagano; Masahiro Katsurada; Yuichiro Yasuda; Kazuyuki Kobayashi; Yoshihiro Nishimura
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 4.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 5.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Chris Bullen; Rachna Begh; Lindsay F Stead; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2016-09-14

Review 6.  Psychosocial interventions for supporting women to stop smoking in pregnancy.

Authors:  Catherine Chamberlain; Alison O'Mara-Eves; Sandy Oliver; Jenny R Caird; Susan M Perlen; Sandra J Eades; James Thomas
Journal:  Cochrane Database Syst Rev       Date:  2013-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.